51376 Federal Register / Vol. 76, No. 160 / Thursday, August 18, 2011 / Notices 

section 1111 of the Public Health 

Service Act, codified at 42 U.S.C. 300b– 

10, also provides advice and 

recommendations concerning grants and 

projects authorized under section 1109 

of the Public Health Service Act (42 

U.S.C. 300b–8). 

Agenda: The meeting will include a 

review and reflection of the previous 24 

meetings and a look forward. The 

agenda will include topics related to the 

past, present, and future work of the 

Committee, including: (1) A 

presentation of the previous, current 

and future endeavors of the External 

Review Workgroup’s activities; (2) an 

update from the Evidence Evaluation 

and Methods workgroup’s progress on 

developing the Decision Process Tree; 

(3) review of previous reports, 

workgroups and publications from the 

Committee and next steps for public 

health genetics; and (4) discussion and 

presentations on the previous and 

continued work and reports of the 

Advisory Committee’s subcommittees 

on laboratory standards and procedures, 

follow-up and treatment, and education 

and training. Proposed agenda items are 

subject to change as priorities dictate. 

You can locate the Agenda, Committee 

Roster and Charter, presentations, and 

meeting materials at the home page of 

the Advisory Committee’s Web site at 

http://www.hrsa.gov/ 

heritabledisorderscommittee/. 

Public Comments: This meeting will 

include an extended public comment 

period during the morning session on 

September 22, 2011. Members of the 

public can submit written comments 

and/or present oral comments during 

the public comment period of the 

meeting. Those individuals who want to 

make oral comments are requested to 

register online by Tuesday, September 

20, 2011, at http://altarum.cvent.com/ 

event/SACHDNC092011. Requests 

should contain the name, address, 

telephone number, and any professional 

or business affiliation of the person 

desiring to make an oral comment. 

Groups having similar interests are 

requested to combine their comments 

and present them through a single 

representative. Written comments 

should be e-mailed no later than 

Tuesday, September 20, 2011 for 

consideration. Oral and written public 

comment will be included in the 

transcripts of the meeting and will be 

posted to the committee’s Web site. 

Written comments should contain the 

name, address, telephone number, and 

any professional or business affiliation 

of the author. Submit written comments 

to Maureen Ball, Meetings Coordinator, 

Conference and Meetings Management, 

Altarum Institute, 1200 18th Street, 

NW., Suite 700, Washington, DC 20036, 

telephone: 202 828–5100; fax: 202 785– 

3083, or e-mail: 

conferences@altarum.org. 

Contact Person: Anyone interested in 

obtaining other relevant information 

should write or contact Alaina M. 

Harris, Maternal and Child Health 

Bureau, Health Resources and Services 

Administration, Room 18A–19, 

Parklawn Building, 5600 Fishers Lane, 

Rockville, Maryland 20857, Telephone 

(301) 443–0721, aharris@hrsa.gov. More 

information on the Advisory Committee 

is available at http://mchb.hrsa.gov/ 

heritabledisorderscommittee. 

Dated: August 12, 2011. 

Reva Harris, 

Acting Director, Division of Policy and 

Information Coordination. 

[FR Doc. 2011–21092 Filed 8–17–11; 8:45 am] 

BILLING CODE 4165–15–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Government-Owned Inventions; 

Availability for Licensing 

AGENCY: National Institutes of Health, 

Public Health Service, HHS. 

ACTION: Notice. 

SUMMARY: The inventions listed below 

are owned by an agency of the U.S. 

Government and are available for 

licensing in the U.S. in accordance with 

35 U.S.C. 207 to achieve expeditious 

commercialization of results of 

federally-funded research and 

development. Foreign patent 

applications are filed on selected 

inventions to extend market coverage 

for companies and may also be available 

for licensing. 

ADDRESSES: Licensing information and 

copies of the U.S. patent applications 

listed below may be obtained by writing 

to the indicated licensing contact at the 

Office of Technology Transfer, National 

Institutes of Health, 6011 Executive 

Boulevard, Suite 325, Rockville, 

Maryland 20852–3804; telephone: 301– 

496–7057; fax: 301–402–0220. A signed 

Confidential Disclosure Agreement will 

be required to receive copies of the 

patent applications. 

Quantitative Measurement of 

Syndesmophytes in Ankylosing 

Spondylitis Using Computed 

Tomography (CT) 

Description of Technology: 

Syndesmophyte (abnormal bone) growth 

in the spine is a hallmark of Ankylosing 

Spondylitis, a type of inflammatory 

arthritis. Syndesmophyte growth is 

currently monitored using semiquantitative scoring of radiographs, but 

radiographs consider only a small part 

of the vertebra, and the method is 

subject to reader error. Because 

syndesmophytes grow slowly, 

radiographs also lack sensitivity. The 

invention provides a method to measure 

syndesmophytes using data from 

computed tomography scans of the 

lumbar spine. It provides computer 

algorithm that fully quantitates 

syndesmophyte volumes in threedimension space. This method allows 

precise and accurate measurement of 

the presence and rate of growth of 

syndesmophytes over time, which for 

the first time will permit testing of 

whether any treatments can slow the 

progression of this type of spinal 

arthritis. 

Potential Commercial Applications: 

• The method would be useful for 

clinical trials of drugs against 

Syndesmophyte growth. 

• Because of the improved precision, 

achieving statistical significance in 

assessing the efficacy of a drug would 

require smaller samples. 

Competitive Advantages: 

• The present method is more 

automated than existing methods. 

• The method is more precise and 

sensitive than existing methods, thus 

providing more reliable statistical 

analysis and improved planning in 

treatment regimen. 

Development Stage: In vivo data 

available (human). 

Inventors: Sovira Tan (NIAMS), et al. 

Publication: Tan S, Yao J, Ward MM, 

Yao L, Summers RM. Computer aided 

evaluation of ankylosing spondylitis 

using high-resolution CT. IEEE Trans 

Med Imaging 2008 Sep;27(9):1252–1267. 

[PMID 18779065]. 

Intellectual Property: HHS Reference 

No. E–167–2011/0—Software. Patent 

protection is not being pursued for this 

technology. 

Licensing Contact: Michael 

Shmilovich, Esq.; 301–435–5019; 

shmilovm@mail.nih.gov. 

Collaborative Research Opportunity: 

The National Institute of Arthritis and 

Musculoskeletal and Skin Diseases is 

seeking statements of capability or 

interest from parties interested in 

collaborative research to further 

develop, evaluate or commercialize this 

technology. For collaboration 

opportunities, please contact Brian W. 

Bailey, Ph.D. at bbailey@mail.nih.gov. 

mstockstill on DSK4VPTVN1PROD with NOTICES

Federal Register / Vol. 76, No. 160 / Thursday, August 18, 2011 / Notices 51377 

An Automated Method for Precise 

Measurement of Vertebral Body Height 

and Intervertebral Disk Height Using 

Computed Tomography 

Description of Technology: Vertebral 

fractures due to osteoporosis result in 

loss of vertebral height. Degenerative 

disk disease in the spine results in loss 

of disk height. Currently, radiography 

and magnetic resonance imaging are 

used to assess vertebral and disk height, 

and measurements are done manually. 

The present invention offers improved 

method to measure vertebral and disk 

heights. The invention provides 

computer algorithm that substantially 

automates the task, and uses computed 

tomography. The advantage of 

computed tomography over radiography 

is that of 3D imaging over 2D imaging. 

Computed tomography’s advantage over 

MRI is better image resolution. The 

combination of automation and superior 

imaging capability makes the method 

substantially more precise than previous 

ones. This allows better detection of 

changes in vertebral height and disk 

height over time, and thus aids in the 

planning of appropriate medical 

treatment in cases associated with the 

loss of vertebral or disk heights, such as 

in osteoporosis for example. 

Potential Commercial Applications: 

• The method would be useful for 

clinical trials of drugs for osteoporosis. 

• Because of the improved precision, 

achieving statistical significance in 

assessing the efficacy of a drug would 

require smaller samples. 

Competitive Advantages: 

• The present method is semiautomated. 

• The method is more precise and 

sensitive than existing methods, thus 

providing more reliable statistical 

analysis and improved planning in 

treatment regimen. 

Development Stage: In vivo data 

available (human). 

Inventors: Sovira Tan (NIAMS), et al. 

Intellectual Property: HHS Reference 

No. E–166–2011/0—Software. Patent 

protection is not being pursued for this 

technology. 

Licensing Contact: Michael 

Shmilovich, Esq.; 301–435–5019; 

shmilovm@mail.nih.gov. 

Collaborative Research Opportunity: 

The National Institute of Arthritis and 

Musculoskeletal and Skin Diseases is 

seeking statements of capability or 

interest from parties interested in 

collaborative research to further 

develop, evaluate or commercialize this 

technology. For collaboration 

opportunities, please contact Brian W. 

Bailey, Ph.D. at bbailey@mail.nih.gov. 

Monoclonal Antibodies Against 

Poliovirus 

Description of Technology: Early 

work by Hammond et al. showed 

gamma globulin to be effective for the 

prevention of poliomyelitis. Therefore, 

passive immunotherapy could be 

another way to treat chronic excretors. 

Even though prior attempts to use 

intravenous immunoglobulin (IVIG) and 

breast milk were unsuccessful, there is 

reason to think that higher doses of 

antipoliovirus antibodies could result in 

complete clearance of poliovirus from 

chronically infected individuals. Six 

poliovirus-neutralizing MAbs were 

recovered from a combinatorial Fab 

phage display library constructed from 

bone marrow-derived lymphocytes of 

immunized chimpanzees. The six MAbs 

neutralized vaccine strains and virulent 

strains of poliovirus. Five MAbs were 

serotype specific, while one MAb crossneutralized serotypes 1 and 2. Both 

serotype 2-specific antibodies 

recognized antigenic site 1. No escape 

mutants to serotype 3-specific MAbs 

could be generated. The administration 

of a serotype 1-specific MAb to 

transgenic mice susceptible to 

poliovirus at a dose of 5 μg/mouse 

completely protected them from 

paralysis after challenge with a lethal 

dose of wild-type poliovirus. Moreover, 

MAb injection 6 or 12 h after virus 

infection provided significant 

protection. This application claims the 

antibodies described above and methods 

for their use. 

Potential Commercial Applications: 

• Prophylaxis/therapeutic for 

poliovirus. 

• Post-exposure emergency 

prophylaxis of poliovirus. 

Competitive Advantages: 

• No humanization required. 

• Highly potent neutralizing 

antibodies. 

• Biological materials available. 

Development Stage: 

• Pre-clinical. 

• In vitro data available. 

• In vivo data available (animal). 

Inventors: Zhaochun Chen, Robert H. 

Purcell, Konstantin Chumakov (NIAID). 

Publication: Chen Z, et al. 

Chimpanzee-human monoclonal 

antibodies for treatment of chronic 

poliovirus excretors and emergency 

postexposure prophylaxis. J Virol. 2011 

May;85(9):4354–4362. [PMID: 

21345966]. 

Intellectual Property: HHS Reference 

No. E–076–2011/0—U.S. Provisional 

Application No. 61/443,915 filed 17 Feb 

2011. 

Licensing Contact: Peter Soukas, J.D.; 

301–435–4646; soukasp@mail.nih.gov. 

Methods of Treating Giardiasis Using 

FDA-Approved Compounds 

Description of Technology: This 

technology includes a group of at least 

twenty-nine, diverse, commercially 

available compounds that are newly 

identified for activity against Giardia 

lamblia parasites. At least six of the 

candidate compounds, Bortezomib, 

Decitabine, Hydroxocobalamin, 

Amlexanox, Idarubicin, and Auranofin 

have preexisting FDA approval for 

human use for other (non-Giardia) 

conditions. Another three compounds, 

Fumagillin, Nitarsone and Carbadox 

have preexisting approval for veterinary 

use for non-Giardia conditions. 

Additional active compounds identified 

include: Acivicin, Riboflavin butyrate, 

BTO–1, GW9662, Dinitroph-dfgp, 

Deserpidine, Tetramethylthiuram 

disulsulfide, Disulfiram, Mitoxantrone, 

Ecteinascidin 743, 17- 

allyaminogeldanamycin, Carboquone 

and Nocodazole. The anti-Giardial 

activity of these compounds presents a 

cost saving opportunity for the rapid 

development of new, better tolerated 

treatments for the most prevalent 

human intestinal parasite infection in 

the United States and the world. 

Potential Commercial Applications: 

• Treatment of Giardia in humans. 

• Treatment of Giardia in animals— 

dogs and cats. 

Competitive Advantages: These 

compounds have currently been 

approved for human and veterinary uses 

of other indications which provides an 

opportunity to greatly reduce risk and 

pre-market investments both in terms of 

time and costs associated with 

development and regulatory approval 

for new Giardia applications including 

the drug resistant Giardiasis. 

Development Stage: 

• Early-stage. 

• Pre-clinical. 

• In vitro data available. 

Inventors: 

• Wei Zheng, Catherine Chen, Juan J. 

Marugan, Noel T. Southall, Christopher 

P. Austin (NHGRI). 

• Osnat Hertzberg, Luidmila 

Kulakova, Andrey Galkin (Institute for 

Bioscience & Biotechnology Research, 

University of Maryland). 

Publication: Chen CZ, et al. Highthroughput Giardia lamblia viability 

assay using bioluminescent ATP content 

measurements. Antimicrob Agents 

Chemother. 2011 Feb;55(2):667–675. 

[PMID 21078930]. 

Intellectual Property: HHS Reference 

No. E–211–2010/1—U.S. Provisional 

Application No. 61/411,509 filed 09 

Nov 2010. 

Licensing Contact: Tedd Fenn; 301– 

435–5031; Tedd.Fenn@nih.gov. 

mstockstill on DSK4VPTVN1PROD with NOTICES

51378 Federal Register / Vol. 76, No. 160 / Thursday, August 18, 2011 / Notices 

Collaborative Research Opportunity: 

The NHGRI is seeking statements of 

capability or interest from parties 

interested in collaborative research to 

further develop, evaluate, or 

commercialize Novel Compounds for 

Treatment of Giardiasis. For 

collaboration opportunities, please 

contact Claire Driscoll, NHGRI, at 

cdriscol@mail.nih.gov. 

Dated: August 12, 2011. 

Richard U. Rodriguez, 

Director, Division of Technology Development 

and Transfer, Office of Technology Transfer, 

National Institutes of Health. 

[FR Doc. 2011–21155 Filed 8–17–11; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute on Alcohol Abuse 

and Alcoholism; Amended Notice of 

Meeting 

Notice is hereby given of a meeting of 

the National Advisory Council on 

Alcohol Abuse and Alcoholism, 

September 12, 2011, 3:30 p.m. to 5:30 

p.m., September 13, 2011, 9 a.m. to 1 

p.m., National Institutes of Health, 

Building 1, 1 Center Drive, Wilson Hall, 

Bethesda, MD 20892 which was 

published in the Federal Register on 

June 29, 2011, 76FRN2011–16858. 

The meeting time has changed on 

September 12, 2011 from 2:45 p.m. to 

5:30 p.m. The location of the meeting 

will remain the same. 

Dated: August 11, 2011. 

Anna P. Snouffer, 

Deputy Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2011–21126 Filed 8–17–11; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute on Deafness and 

Other Communication Disorders; 

Notice of Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute on 

Deafness and Other Communication 

Disorders Special Emphasis Panel, P50 

Review. 

Date: September 27, 2011. 

Time: 3 p.m. to 6 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6120 

Executive Blvd., Rockville, MD 20852, 

(Telephone Conference Call). 

Contact Person: Christine A. Livingston, 

PhD, Scientific Review Officer, Division of 

Extramural Activities, National Institutes of 

Health/NIDCD, 6120 Executive Blvd.—MSC 

7180, Bethesda, MD 20892, (301) 496–8683, 

livingsc@mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.173, Biological Research 

Related to Deafness and Communicative 

Disorders, National Institutes of Health, HHS) 

Dated: August 12, 2011. 

Anna P. Snouffer, 

Deputy Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2011–21150 Filed 8–17–11; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Cancer Institute; Notice of 

Meeting 

Pursuant to section 10(a) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of a meeting of the 

National Cancer Institute Board of 

Scientific Advisors. 

The meeting will be open to the 

public, with attendance limited to space 

available. Individuals who plan to 

attend and need special assistance, such 

as sign language interpretation or other 

reasonable accommodations, should 

notify the Contact Person listed below 

in advance of the meeting. 

Name of Committee: National Cancer 

Institute Board of Scientific Advisors, caBIG 

Oversight Ad hoc Subcommittee. 

Date: August 25, 2011. 

Time: 11 a.m. to 1 p.m. 

Agenda: New Business, caBIG Initiatives 

and Oversight Interaction. 

Place: National Institutes of Health, 6116 

Executive Boulevard, 8th Floor, Rm. 8018, 

Rockville, MD 20852, (Telephone Conference 

Call). 

Contact Person: John Czajkowski, MPA, 

Deputy Director for Management, Office of 

the Director, National Cancer Institute, 

National Institutes of Health, 31 Center Drive, 

Rm. 11A48, Bethesda, MD 20892, 301–435– 

2455, john.czajkowski@nih.gov. 

This notice is being published less than 15 

days prior to the meeting due to scheduling 

conflicts. 

Any interested person may file written 

comments with the committee by forwarding 

the statement to the Contact Person listed on 

this notice. The statement should include the 

name, address, telephone number and when 

applicable, the business or professional 

affiliation of the interested person. 

Information is also available on the 

Institute’s/Center’s home page: 

deainfo.nci.nih.gov/advisory/bsa.htm, where 

an agenda and any additional information for 

the meeting will be posted when available. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.392, Cancer Construction; 

93.393, Cancer Cause and Prevention 

Research; 93.394, Cancer Detection and 

Diagnosis Research; 93.395, Cancer 

Treatment Research; 93.396, Cancer Biology 

Research; 93.397, Cancer Centers Support; 

93.398, Cancer Research Manpower; 93.399, 

Cancer Control, National Institutes of Health, 

HHS) 

Dated: August 12, 2011. 

Anna P. Snouffer, 

Deputy Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2011–21146 Filed 8–17–11; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Cancer Institute Amended 

Notice of Meeting 

Notice is hereby given of a change in 

the meeting of the National Cancer 

Advisory Board, September 13, 2011, 9 

a.m. to September 13, 2011, 5 p.m., 

National Institutes of Health National 

Institutes of Health, Building 31, 31 

Center Drive, Conference Room 10, 

Bethesda, MD 20892 which was 

published in the Federal Register on 

August 10, 2011, 76 FR 49493. 

This notice is amended to add the 

National Cancer Advisory Board Ad hoc 

Subcommittee on Global Cancer 

Research meeting. The meeting will 

convene on September 12, 2011 from 

6:30 to 8:30 p.m. in the Diplomat/ 

Ambassador room at the Bethesda 

Regency Hyatt, One Metro Center, 

Bethesda, MD 20814. 

Dated: August 12, 2011. 

Anna P. Snouffer, 

Deputy Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2011–21137 Filed 8–17–11; 8:45 am] 

BILLING CODE 4140–01–P 

mstockstill on DSK4VPTVN1PROD with NOTICES